The European Medicines Agency (EMA) is set to enhance its support for medicinal product management by introducing monthly Q&A clinics dedicated to the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service. These online sessions aim to address queries and provide clarity on various aspects of the XEVMPD system.
Event Details and Registration
Scheduled to commence on December 18, 2025, the initial session will run from 14:00 to 15:00 Amsterdam time (CET). Participants can join the live broadcast through the EMA’s official platform. Registration for these clinics is currently open, allowing stakeholders to secure their spots in advance. Additionally, video recordings of each session will be available post-event, ensuring accessibility for those unable to attend live.
Comprehensive Support for SPOR Master Data
Beyond the XEVMPD service, the EMA is also offering dedicated Q&A clinics focusing on Substance, Organisation, Referentials Management Services, and Substance, Product, Organisation, and Referential (SPOR) master data. These sessions are designed to provide in-depth support and guidance, facilitating better management and utilization of regulatory data among professionals in the pharmaceutical sector.
- Enhanced understanding of XEVMPD functionalities
- Direct access to EMA experts for complex queries
- Improved data management practices for regulatory compliance
- Opportunities for feedback to shape future EMA services
The introduction of these monthly clinics underscores the EMA’s commitment to fostering a collaborative environment where regulatory data management can be effectively navigated. By providing continuous support and readily available expert advice, the EMA ensures that stakeholders remain informed and equipped to handle the evolving demands of medicinal product regulation.
Participants are encouraged to take advantage of these sessions to deepen their knowledge of the XEVMPD service and related management tools. The availability of recordings further enhances the EMA’s dedication to accessibility and ongoing education. As the pharmaceutical landscape continues to advance, such initiatives play a crucial role in maintaining high standards of safety and efficacy in medicinal products across the European Union.
Staying informed through EMA’s Q&A clinics can significantly benefit professionals by streamlining their regulatory processes and ensuring compliance with the latest guidelines. Engaging with these resources equips stakeholders with the necessary tools to contribute to the overall effectiveness and reliability of the European medicinal product framework.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
